Score Overview
Explore the 2021 public Archive ranking →
Where Sarepta Therapeutics Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- SRPT
2008: 94.8% · 2021: 90.7% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 18.80 | — |
1 Year2025-09-26 | $ 18.36 | 2.40% |
5 Years2021-09-28 | $ 92.01 | -79.57% |
10 Years2016-09-28 | $ 62.24 | -69.79% |
20 Years2006-09-28 | $ 21.12 | -10.98% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 |
|---|---|---|---|---|---|
| Price | $ 18.80 | $ 18.36 | $ 92.01 | $ 62.24 | $ 21.12 |
| Return | — | 2.40% | -79.57% | -69.79% | -10.98% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 1.97B | -$ 136M | $ 788M |
| 2025 | $ 2.19B | -$ 713M | $ 939M |
| 2024 | $ 1.90B | $ 235M | $ 1.35B |
| 2023 | $ 1.24B | -$ 535M | $ 1.67B |
| 2022 | $ 933M | -$ 703M | $ 1.98B |
| 2021 | $ 701M | -$ 418M | $ 2.11B |
| 2020 | $ 540M | -$ 554M | $ 1.93B |
| 2019 | $ 380M | -$ 715M | $ 1.12B |
| 2018 | $ 301M | -$ 361M | $ 1.17B |
| 2017 | $ 154M | -$ 50M | $ 1.07B |
| 2016 | $ 5M | -$ 267M | $ 317M |
| 2015 | $ 1M | -$ 220M | $ 192M |
| 2014 | $ 9M | -$ 135M | $ 210M |
| 2013 | $ 14M | -$ 111M | $ 256M |
| 2012 | $ 37M | -$ 121M | $ 187M |
| 2011 | $ 46M | -$ 2M | $ 39M |
| 2010 | $ 29M | -$ 32M | $ 33M |
| 2009 | $ 17M | -$ 25M | $ 48M |
| 2008 | $ 21M | -$ 23M | $ 11M |
| 2007 | $ 10M | -$ 27M | $ 25M |
| 2006 | $ 115.29K | -$ 31M | $ 33M |
| 2005 | $ 4M | -$ 16M | $ 47M |
| 2004 | $ 430.46K | -$ 24M | $ 19M |
| 2003 | $ 969.87K | -$ 14M | $ 37M |
| 2002 | $ 836.78K | -$ 29M | $ 19M |
| 2001 | $ 706.1K | -$ 26M | $ 25M |
| 2000 | $ 1M | -$ 9M | $ 32M |
| 1999 | $ 100K | -$ 8M | $ 11M |
| 1998 | $ 200K | -$ 26M | $ 8M |
| IPO1997 | $ 100K | -$ 3M | $ 17M |
Sarepta Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 540M to $ 2.19B and net income went from -$ 554M to -$ 713M. Revenue increased in 4 of those 5 years; net income in 3.
Across Sarepta Therapeutics Inc's full reported history, from 1997 to 2025, revenue grew from $ 100K to $ 2.19B and net income went from -$ 3M to -$ 713M. Revenue increased in 66% of the years measured; net income in 45%.
Sarepta Therapeutics Inc currently holds a 20-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.
Membership
Continue SRPT’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
